<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004178</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067388</org_study_id>
    <secondary_id>BIDMC-941101148</secondary_id>
    <secondary_id>NEDH-941101148</secondary_id>
    <secondary_id>NCI-V99-1577</secondary_id>
    <nct_id>NCT00004178</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Patients With Cancer</brief_title>
  <official_title>Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roger Williams Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Roger Williams Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting a gene that has been created in the laboratory into a person's white
      blood cells may make the body build an immune response to kill cancer cells.

      PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who
      have cancer that has not responded to previous therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and maximum tolerated dose of T cells activated in vitro and
           modified with chimeric anti-CEA immunoglobulin T cell receptors (Ig TCR) in patients
           with CEA expressing adenocarcinoma.

        -  Determine the pharmacokinetics of this regimen by the persistence of modified T cells in
           the blood of these patients.

        -  Evaluate the immunogenicity of murine sequences in chimeric anti-CEA Ig TCR.

        -  Assess immunologic parameters which correlate with the efficacy of this regimen in these
           patients.

        -  Evaluate, in a preliminary manner, the efficacy of this regimen in patients with CEA
           bearing tumors.

      OUTLINE: This is a dose escalation study.

      Peripheral blood lymphocytes (PBL) are harvested. PBL are activated in vitro and then
      modified with recombinant chimeric anti-CEA immunoglobulin T cell receptors (Ig TCR). Ig TCR
      modified T cells are reinfused over 30-60 minutes.

      The estimated maximum tolerated dose (MTD) is defined as the dose at which 2 of 6 patients
      experience unacceptable toxicity. If the MTD is not reached within the first cohort, a second
      cohort of 3 patients then receives 4 doses of modified T cells at a higher dose.

      Patients are followed every 2 weeks for 2 months.

      PROJECTED ACCRUAL: A total of 6-9 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven CEA expressing adenocarcinoma

               -  Serum CEA levels greater than 10 ng/mL

               -  Failed standard therapy

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  0-2

        Life expectancy:

          -  Greater than 2 months

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No significant hepatic disease

          -  Bilirubin no greater than 3 mg/dL

          -  No active clinical disease caused by hepatitis B

        Renal:

          -  No significant renal disease

          -  Creatinine no greater than 3 mg/dL

        Cardiovascular:

          -  No significant cardiovascular disease

        Pulmonary:

          -  No significant pulmonary disease

        Other:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No significant endocrine, rheumatologic, or allergic disease

          -  No active clinical disease caused by cytomegalovirus or tuberculosis

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard P. Junghans, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>April 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2004</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Richard Junghans</name_title>
    <organization>Roger Williams Medical Center</organization>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage III vaginal cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>recurrent vaginal cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>duct cell adenocarcinoma of the pancreas</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>intestinal adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>diffuse adenocarcinoma of the stomach</keyword>
  <keyword>mixed adenocarcinoma of the stomach</keyword>
  <keyword>mucinous adenocarcinoma of the colon</keyword>
  <keyword>signet ring adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>mucinous adenocarcinoma of the rectum</keyword>
  <keyword>signet ring adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma with squamous metaplasia of the gallbladder</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>vaginal adenocarcinoma</keyword>
  <keyword>vaginal clear cell adenocarcinoma</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>adenocarcinoma of the bladder</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>adenocarcinoma of unknown primary</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

